Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS-5635 Injection in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and immunogenicity of HRS-5635 injection as compared to the placebo arm in nucleos(t)ide analogue-suppressed HBeAg-negative patients with chronic hepatitis B. The total duration of the study, including screening (up to 4 weeks), the double-blind treatment stage (60 weeks),NAs-only treatment stage(12 weeks) and the off-treatment follow-up (24 weeks), is up to approximately 100 weeks at maximum for each participant.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Yi Lu
- Número de telefone: 0518-82342973
- E-mail: minghao.lyu@hengrui.com
Locais de estudo
-
-
Guangzhou
-
Guangzhou, Guangzhou, China, 510515
- Recrutamento
- Nanfang Hospital, Southern Medical University
-
Investigador principal:
- Jinlin Hou
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Chronic hepatitis B defined as HBV infection documented for at least 6 months prior to screening;
- Virologically suppressed on nucleoside or nucleotide analogues treatment with HBV DNA below the lower limit of quantitation;
- HBeAg negative at screening;
- On commercially available NAs monotherapy for at least 24 weeks before randomization, and the dosing regimen remained unchanged for at least 4 weeks before randomization;
- Need to take effective contraceptive measures;
- Volunteer to sign an informed consent.
Exclusion Criteria:
- History of cirrhosis or clinical evidence of hepatic decompensation, confirmed or suspected liver cancer, with other liver diseases other than chronic hepatitis B that may affect the evaluation of the study;
- With autoimmune disease;
- History of solid organ transplantation or hematopoietic stem cell transplantation;
- Clinically significant and unstable or uncontrolled severe cardiovascular and cerebrovascular diseases;
- Malignant tumors were diagnosed within 5 years prior to randomization;
- Major trauma or major surgery within the 12 weeks prior to randomization, or surgical plans or other treatment during the study period which the investigators determined may influence the evaluation of the study results;
- Laboratory tests during the screening period were obviously abnormal;
- Prolonged ECG QTcF or other clinically significant abnormal results that may pose a significant safety risk to the subject during the screening period;
- History of drug use, alcohol or drug abuse in the 12 months prior to randomization;
- Participated in clinical study of other drugs (received experimental drugs);
- Pregnant or nursing women;
- Allergic to a drug ingredient or component;
- Other reasons for ineligibility as judged by the investigators.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
|
Placebo, administered by subcutaneous injection. |
|
Experimental: HRS-5635 Injection
|
HRS-5635 Injection, administered by subcutaneous injection; |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Percentage of participants with sustained HBV DNA suppression and HBsAg loss within 24 weeks after discontinuation of all HBV therapy
Prazo: 24 weeks after discontinuation of all CHB treatment
|
24 weeks after discontinuation of all CHB treatment
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Percentage of participants with sustained HBV DNA suppression and HBsAg < 100 IU/mL
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with sustained HBV DNA suppression and HBsAg < 10 IU/mL
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with sustained HBV DNA suppression
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg < 100 IU/mL
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg < 10 IU/mL
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Changes from baseline in mean log10 HBsAg levels
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg loss
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg seroconversion
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBeAb positive
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with virologic breakthrough
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with drug resistance
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Relapse rate after discontinuation of NAs therapy
Prazo: Up to 24 weeks after discontinuation of NAs treatment
|
Up to 24 weeks after discontinuation of NAs treatment
|
|
Treatment-emergent adverse events
Prazo: Up to 24 weeks after discontinuation of NAs treatment
|
Up to 24 weeks after discontinuation of NAs treatment
|
|
Percentage of participants with detectable anti-drug antibodies
Prazo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants who meet the criteria for stopping nucleos(t)ide analogue (NA) therapy
Prazo: Week 72 and Week 96
|
Week 72 and Week 96
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
Outros números de identificação do estudo
- HRS-5635-301
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .